GWP
AKBA icon

Gen-Wealth Partners’s Akebia Therapeutics AKBA Stock Holding History

Gen-Wealth Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.19K Hold
2,295
– – ﹤0.01% 619
2025
Q4 		$3.69K Hold
2,295
– – ﹤0.01% 581
2025
Q3 		$6.26K Buy
+2,295
New +$7.63K ﹤0.01% 552

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Gen-Wealth Partners's AKBA Position: Q1 2026 in Review

Gen-Wealth Partners held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 2,295 shares worth $3.19K. The position accounts for ﹤0.01% of the portfolio, ranked #619.

Gen-Wealth Partners first reported a position in AKBA in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.26K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Gen-Wealth Partners held 2,295 shares of Akebia Therapeutics worth $3.19K as of Q1 2026.
  • Gen-Wealth Partners left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #619 holding.
  • Gen-Wealth Partners first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Gen-Wealth Partners's Akebia Therapeutics position peaked at $6.26K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.